Provider Statement:

This continuing medical education activity is provided in collaboration with

Educational Partner:

Support Statement:

This activity is supported by educational grants from Bristol-Myers Squibb; Genentech, Inc.; and Merck & Co., Inc.

Activity Chair:

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology
Yale School of Medicine
Yale Cancer Center
Smilow Cancer Hospital
New Haven, CT


Fred R. Hirsch, MD, PhD
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair in Lung Cancer
Associate Director for International Programs
University of Colorado Cancer Center
Aurora, CO

Karen Kelly, MD
Professor of Medicine
Associate Director for Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

Naiyer Rizvi, MD
Director, Thoracic Oncology & Phase I Immunotherapeautics
Columbia University Medical Center
New York, NY


Charles A. Butts, MD, FRCPC

Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP

Activity Details

Credit Type: AMA PRA Category 1 Credit
Credit Amount: 1.5 credit hour
Release Date: October 27, 2016
Expiration Date: October 26, 2017
Estimated Time to Complete Activity: 1.5 hours
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Target Audience:

The intended audience for this activity is medical oncologists, radiation oncologists, pathologists, pulmonologists and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives:

Upon successful completion of this educational activity, participants should be better able to:

  • Review the latest clinical data on the efficacy, safety, and recommended usage of new and emerging immunotherapies for the treatment of NSCLC.
  • Differentiate new and emerging immune checkpoint inhibitors based on mechanism of action.
  • Evaluate the clinical applicability of combination immunotherapy with chemotherapy, targeted therapies, and/or other modalities in NSCLC.
  • Apply knowledge of the updated pathologic classification scheme for NSCLC to the selection of diagnostic modalities and treatments.
  • Describe the use of current and emerging biomarkers in determining prognosis and choosing therapies for patients with NSCLC.
  • Assess biopsy techniques for acquiring adequate tissue for morphological, immunohistochemical, and molecular testing.


Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

Yale School of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 27, 2016 through October 26, 2017.

How To Participate in this Activity and Obtain CME Credit:

To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Yale School of Medicine will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty member report the following relationship(s):
Roy S. Herbst, MD, PhD
Consulting Fee: AstraZeneca, Genentech/Roche, Merck, Pfizer
Contracted Research: Genentech, Merck
Scientific Advisory Boards: Biothera, Diatech, Kolltan

Fred R. Hirsch, MD, PhD
Consulting Fees: AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, HTG, Lilly, Merck, Ventana

Naiyer Rizvi, MD
Consulting Fees: AstraZeneca, Merck, Novartis, Roche
Ownership Interest: Gritstone Oncology

Karen Kelly, MD
Royalty: UpToDate
Consulting Fees: Ariad, AstraZeneca, Boehringer Ingelheim, Clovis, Genentech, Lilly
Contracted Research: AbbVie, Celgene, EMD Serono, Genentech, Gilead, Lilly, Millennium, Novartis

Naiyer Rizvi, MD
Consulting Fees: AbbVie, Celgene, EMD Serono, Genentech, Gilead, Lilly, Millennium, Novartis, AstraZeneca, Merck, Novartis, Roche
Ownership Interest: Gritstone Oncology

Reviewers report the following relationship(s):
Charles A. Butts MD, FRCPC
Consulting Fee: AstraZeneca, Bristol Myers Squibb, Merck, Pfizer
Speakers Bureau: Merck, Pfizer
Contracted Research: AstraZeneca, Bristol Myers Squibb, Lilly, Merck, Novartis, Pfizer

Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Yale School of Medicine and Vindico Medical Education Staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Yale School of Medicine.

Unlabeled and Investigational Usage:

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Yale School of Medicine and Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Yale School of Medicine, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Yale CME: 203-785-4578 or

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.